Evidence that one of the #Covid19 vaccines works sufficiently well to warrant its use could make testing the others seriously complicated, writes in a meaty discussion of vaccine trial ethics.
ICYMI makes a vital point: The 1st #COVID19 #vaccines to get a nod & go into mass use are unlikely to be the best. But as Big Money skews to the front of the race, far superior products in the pipeline may get lost.
Early approval of a #COVID19 #vaccine could stymie the hunt for better ones ⁦⁩ ⁦⁩ #ChristineGrady
Could an EUA for a COVID-19 vaccine that's marginally effective complicate attempts to find better ones? Could it complicate studies of its own true worth? A knot of ethical dilemmas come with the first success--and they go well beyond prioritization.
Glad to see this coverage of last week's excellent NIH Ethics Grand Rounds discussion re. "vexing" challenges associated with early approval of a COVID-19 vaccine --featuring colleagues Christine Grady and Joseph Millum
The first COVID-19 vaccine to cross the finish line could pose big problems for other - better - vaccines still in trials, reports.
Early approval of a COVID-19 vaccine could stymie the hunt for better ones
More on the vaccine EUA question from Jon Cohen at Science - and it's clear that not even experts in the field all agree on what to do about its effect on the clinical trials
Early approval of a COVID-19 vaccine could stymie the hunt for better ones via